4//SEC Filing
Stagg Robert 4
Accession 0001567619-18-003957
CIK 0001302573other
Filed
Oct 9, 8:00 PM ET
Accepted
Oct 10, 7:41 PM ET
Size
5.6 KB
Accession
0001567619-18-003957
Insider Transaction Report
Form 4
Stagg Robert
SVP, Clinical R&D
Transactions
- Sale
Common Stock
2018-10-09$2.13/sh−1,686$3,589→ 41,597 total
Footnotes (3)
- [F1]Pursuant to a sell-to-cover election made by the Reporting Person at the time of the initial grant of the restricted stock units ("RSU") award, the shares were sold upon the vesting of restricted stock units solely to cover applicable withholding taxes.
- [F2]This transaction was executed in multiple trades in prices ranging from $2.1082 to $2.1289, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F3]Includes 31,251 RSUs. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof.
Documents
Issuer
OncoMed Pharmaceuticals Inc
CIK 0001302573
Entity typeother
Related Parties
1- filerCIK 0001735050
Filing Metadata
- Form type
- 4
- Filed
- Oct 9, 8:00 PM ET
- Accepted
- Oct 10, 7:41 PM ET
- Size
- 5.6 KB